Clinical Trial Site

Chicago, Illinois 60640

8 studies enrolling now · 38 studies all time

What they study most

ANCA-Associated Vasculitis, Acid Cholesteryl Ester Hydrolase Deficiency, Type 2, Acid Lipase Deficiency, Advanced Breast Cancer, Advanced Hepatocellular Carcinoma, Amyloid Neuropathies, Amyloid Neuropathies, Familial, Amyloidosis, Amyloidosis, Hereditary, Amyloidosis, Hereditary, Transthyretin-Related, Atypical Hemolytic Uremic Syndrome, Atypical Hemolytic-Uremic Syndrome

Studies at this site

• TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy — Recruiting now
• A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy — Recruiting now
• Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease — Recruiting now
• A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris — Recruiting now
• A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma — Recruiting now
• OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer — Recruiting now
• Lysosomal Acid Lipase (LAL) Deficiency Registry — Recruiting now
• A Prospective Sub-Study of the Global Hypophosphatasia Registry — Recruiting now
• Atypical Hemolytic-Uremic Syndrome (aHUS) Registry — Recruiting now
• A Dose Finding Study to Treat Bone Tumor(s) — Stopped early
• A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis — Running, not enrolling
• A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer — Running, not enrolling
• APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy) — Completed
• A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer — Completed
• Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) — Completed
• A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy — Enrolling by invitation
• HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis) — Completed
• A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis — Running, not enrolling
• HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy — Running, not enrolling
• Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures — Stopped early
• Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer — Completed
• A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis — Completed
• APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis — Completed
• The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran) — Completed
• Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants — Completed
• Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants — Completed
• Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome — Stopped early
• A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome — Stopped early
• A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation — Completed
• A Trial Comparing Ferumoxytol With Placebo for the Treatment of Iron Deficiency Anemia — Completed
• A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia — Completed
• Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients — Completed
• Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B — Stopped early
• The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care Treatment — Completed
• A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease — Stopped early
• Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment — Stopped early
• ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) — Completed
• DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis — Completed